GERMANTOWN, Md., Sept. 8, 2022 /PRNewswire/ — Deka Biosciences (“Deka”), a biotech company focused on the development of novel cytokine therapies to treat cancer and inflammatory diseases, announced today the appointment of Charlotte Moser, MD, PhD, MSc, MBA as Chief Medical Officer (CMO) and Deb Kientop, MBA as Vice President, Clinical Operations.
Charlotte Moser, MD, PhD, MSc, MBA, Chief Medical Officer (CMO), Deb Kientop as Vice President, Clinical Operations at Deka Biosciences
“We are proud to have both Charlotte and Deb joining Deka during this exciting time,” said John Mumm, Chief Executive Officer, Deka. “Both come to Deka with strong experience, knowledge and expertise, which will help to deliver life-saving therapies to patients, and drive expansion of our platform, and overall growth of Deka.”
Image: Charlotte Moser, MD, PhD, MSc, MBA, Chief Medical Officer (CMO), Deb Kientop as Vice President, Clinical Operations at Deka Biosciences